openPR Logo
Press release

Epilepsy: Disease Insights and Market Forecasts to 2024 by Pharmascroll

06-06-2018 09:39 AM CET | Health & Medicine

Press release from: Pharmascroll Research and Consulting Private Limited

Epilepsy: Disease Insights and Market Forecasts to 2024

“Epilepsy: Disease Insights and Market Forecasts to 2024” report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Epilepsy disease in the US, EU5 (Germany, France, Italy, Spain, UK), and Japan and the historical & forecasted market size, for Epilepsy, drug wise in $ sales and patient numbers at global level and in the US, EU5 (Germany, France, Italy, Spain, UK), Australia and Canada till 2024.

Geographies covered:
US
Germany
France
Italy
Spain
UK
Japan
Australia
Canada

Drugs covered
Aptiom
Vimpat
Lamictal
Depacon
Keppra
Fycompa
Briviact
Onfi
Lyrica
Sabril
Oxtellar XR
Trokendi XR
Epidiolex
OV935
ZX008
ganaxolone
GWP42006
ZYN002
Padsevonil

Disease Indication Overview:
This section of the report gives the overview of Epilepsy disease indication in detail. The section highlights the basic definition, causes and symptoms of disease and details the types of Epilepsy disease. Further details on the profile of Epilepsy patients, Symptoms experienced by the patients, and disease progression in patients are outlined in the report. The report further highlights the multiple methods through which the patient can be diagnosed for Epilepsy disease.

Epidemiology Forecasts to 2024:
This section of the report provides the overview of Epilepsy diagnosed prevalent and treated patients in the US, EU5 and Japan market year wise starting from 2015 till 2024. The epidemiology numbers in the report have been derived based on numerous studies, survey reports and views of key opinion leaders.

Drugs Overview and Attribute Analysis:
This part of the report highlights the importance of factors influencing the physician prescription decisions in Epilepsy disease including efficacy factors, Tolerability factors, Monitoring requirements and pricing factors.

The report further details the drugs prescribed or expected to be prescribed in Epilepsy disease by the physicians in terms of details about the formulation, molecule, mode of administration and mechanism of action of the drugs, their patent and trial details and the expected impact of drug in the Epilepsy market.

The report further conducts a detailed drug attribute analysis of the drugs currently prescribed or expected to be prescribed in the disease on the parameters of Efficacy, Safety and Tolerability, Convenience of Monitoring and Dosing and Drug’s coverage of the target patient pool.

Drugs and Market Forecast to 2024:
The report in its last section provides sales and patient numbers forecast for the overall Epilepsy market and drug wise forecasts from 2015 till 2024 at Global level and in the US, EU5, Australia and Canada markets. The forecasts are developed based on the detailed drug attribute analysis, conducted by Pharmascroll, as shared in the previous section. It is important to note that the Forecasts conducted by Pharmascroll are not based on simple projections, and are developed meticulously based on a complex forecasting model, owned by Pharmascroll, using multiple assumptions related to launch dates of the products in the market, price of the products, adherence and compliance rates of the products, dosages of the products etc. The forecast models are at the country level and can be developed at the regional level as well.

Why Purchase the Report:
• Robust Market and Drug forecast available at country level
• Forecast in terms of both $ sales and Patient Numbers
• Current and Forecasted Drug treated and Diagnosed Prevalent Patient pool
• Detailed Drug Attribute analysis on multiple Clinical Parameters
• Multiple Countries coverage
• Current Marketed and Pipeline Drugs coverage
• Detailed Disease Insights coverage

To read more about the report please visit https://pharmascroll.com/epilepsy-disease-insights-and-market-forecasts-to-2024/

To enquire about the report or to make a purchase for the report please write to enquiry@pharmascroll.com

Pharmascroll is a diligent business consulting and market research firm focused solely towards pharmaceutical markets. The company consults and researches in majorly chronic disease indications prevalent across the globe. The research conducted by Pharmascroll analysts is targeted to provide analytical and logical answers to the key business questions of the pharmaceutical and medical insights teams and to make better informed business decisions with the detailed relevant information available.

Pharmascroll Research and Consulting Private Ltd
Hi Tech City
Hyderabad
India
Bhawna Gupta
bhawna.gupta@pharmascroll.com
+919776868067

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Epilepsy: Disease Insights and Market Forecasts to 2024 by Pharmascroll here

News-ID: 1071705 • Views:

More Releases from Pharmascroll Research and Consulting Private Limited

Pharmascroll offers Social Media Analytics services for Pharmaceutical and Healt …
Pharmascroll, a renowned Market Research and Business Consulting firm, has been offering research services to Healthcare and Pharmaceutical firms since over 3 years. Pharmascroll has published 70+ syndicated reports in multiple disease indications and has served 30+ market research clients in the Pharmaceutical and Healthcare domain. The firm has catered to customers across Global markets including US, Europe and Asian countries. The firm currently offers research services in the areas
Pharmascroll offering Quality Healthcare and Pharmaceutical Market Research services
Pharmascroll offering Quality Healthcare and Pharmaceutical Market Research serv …
Pharmascroll, a Market Research and Consulting firm, has been a renowned Syndicated and customized research provider across the Healthcare and Pharmaceutical space. Pharmascroll has generated over 75 market research reports in multiple disease indications and has consulted and researched for several Global clients across multiple areas. Global Market Research Industry exceeded 44 Bn USD in revenues in 2015 and around 14% of the market research revenues registered across the Globe
Schizophrenia: Disease Insights & Market Forecasts to 2024 by Pharmascroll
Schizophrenia: Disease Insights & Market Forecasts to 2024 by Pharmascroll
“Schizophrenia: Disease Insights and Market Forecasts to 2024” report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Schizophrenia disease in the US, EU5 (Germany, France, Italy, Spain, UK), and Japan and the historical & forecasted market size, for Schizophrenia, drug wise in $ sales and patient numbers at global level and in the US, EU5 (Germany, France, Italy, Spain, UK), Australia and Canada till 2024. Geographies covered: US Germany France Italy Spain UK Japan Australia Canada Drugs
Parkinson’s: Disease Insights and Market Forecasts to 2024 by Pharmascroll
Parkinson’s: Disease Insights and Market Forecasts to 2024 by Pharmascroll
“Parkinson’s: Disease Insights and Market Forecasts to 2024” report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Parkinson’s disease in the US, EU5 (Germany, France, Italy, Spain, UK), and Japan and the historical & forecasted market size, for Parkinson’s, drug wise in $ sales and patient numbers at global level and in the US, EU5 (Germany, France, Italy, Spain, UK), Australia and Canada till 2024. Geographies covered: US Germany France Italy Spain UK Japan Australia Canada Drugs

All 5 Releases


More Releases for Epilepsy

Epilepsy Market Synthesis and Opportunity Assessment 2030
Epilepsy - Market Insight, Epidemiology And Market Forecast -2030: This report delivers an in-depth understanding of the Epilepsy, historical and forecasted epidemiology as well as the Epilepsy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. The Epilepsy market report provides current treatment practices, emerging drugs, Epilepsy market share of the individual therapies, current and forecasted Epilepsy market Size from 2017 to 2030 segmented
Rising Instances of Pediatric Epilepsy to Pave Novel Growth Avenues in Epilepsy …
Owing to large scale prevalence of epilepsy cases, inclusive of pediatric epilepsy, the market for epilepsy drugs is likely to remain agile in the coming years. Prevalent amongst both male and female demographics alike, epilepsy is a critical condition that affects the brain both partially as well as in whole. Lucrative reimbursement policies, coupled with growing patient awareness about novel therapeutics are likely to reflect favorably on the growth curve
World Congress on Epilepsy and Neuronal Synchronization
Inculcate the latent knowledge in Epilepsy and Neuronal synchrony May 14, 2018: Pulsus Group, host of World Congress on Epilepsy and Neuronal Synchronization, the Conference that discusses the Advanced diagnosis of Epilepsy. Epilepsy 2018 slated during October 15- 16, 2015 at London, UK will schedule and coordinate all meetings with our Editorial Board Members and other experts in the Neurology, Neuropsychiatry & Neuropathology fields across the world. The Epilepsy conference scientific
Epilepsy Therapeutic Pipeline Market Review, 2026
Summary Epilepsy is a brain disorder characterized by recurrent and unpredictable seizures that are caused by sudden, disorderly, and excessive neuronal activity in the brain. It is one of the most common neurological conditions globally. Epilepsy can start at any age and can be a life-long condition. It is diagnosed after a patient has suffered at least one epileptic seizure and is referred to a specialist, where a description of the
Epilepsy - Pipeline Review, H2 2017
ReportsWorldwide has announced the addition of a new report title Epilepsy - Pipeline Review, H2 2017 to its growing collection of premium market research reports. Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Epilepsy - Pipeline Review, H2 2017, provides an overview of the Epilepsy (Central Nervous System) pipeline landscape. Epilepsy is a neurological disorder characterized by the transmission of abnormal signals produced by a group of neurons in the
H2 Epilepsy Market Pipeline Review 2017
"The Report Epilepsy - Pipeline Review, H2 2017 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Epilepsy - Pipeline Review, H2 2017, provides an overview of the Epilepsy (Central Nervous System) pipeline landscape. Epilepsy is a neurological disorder characterized by the transmission of abnormal signals produced by a group of neurons in